EU clears Abbott's blood test for ovarian cancer

01/16/2010 | Clinica (subscription required)

Abbott Laboratories has received EU's CE Mark approval for Architect HE4, a blood test designed to help determine whether pelvic masses are benign or cancerous. The company says its product, co-developed with Fujirebio Diagnostics, is the world's first automated HE4 diagnostic. Abbott also filed an application with the FDA seeking 510(k) clearance for the test.

View Full Article in:

Clinica (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT